Alcon's Newest Antibiotic, Vigamox Ophthalmic Solution, Earns FDA Approval
:Alcon's Newest Antibiotic, Vigamox Ophthalmic Solution, Earns FDA Approval
FORT WORTH, Texas, April 16 /PRNewswire-FirstCall/ -- Alcon, Inc. announces that it received approval from the U.S. Food and Drug Administration (FDA) of its newest antibiotic product, Vigamox (moxifloxacin ophthalmic solution) 0.5 percent, after a six-month review. Vigamox solution contains moxifloxacin, a potent fourth-generation fluoroquinolone antibiotic and is safe and effective for adults and children as young as one year old.
Vigamox solution, dosed only three times a day for seven days, treats bacterial conjunctivitis. Alcon has studied Vigamox solution extensively in three major clinical trials involving more than 1,400 patients.
Moxifloxacin is highly soluble, which allows it to be formulated at a higher concentration (0.5 percent) than other fourth-generation fluoroquinolones. It is very effective against many types of harmful bacteria that infect the surface of the eye. Vigamox solution also shows enhanced coverage of difficult-to-treat Gram-positive bacteria, a class including Staphylococcus and Streptococcus, which account for an estimated 80 percent of eye infections. It is also highly active against Chlamydia, as well as other emerging bacterial threats.
In addition to its therapeutic benefits, Vigamox solution is robust enough to be formulated without the preservative benzalkonium chloride, as a result of the inherent antimicrobial activity of moxifloxacin. It also has a near-neutral pH, resulting in a low incidence of stinging when applied in the eye -- an especially important consideration for children. Furthermore, Vigamox solution provides excellent penetration into ocular tissues. Alcon expects Vigamox solution to be available within several weeks.
Source: Alcon, Inc.
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
From Pandemic to Endemic: How the Protective Face Mask Market Is Evolving
August 3rd 2025Once a symbol of crisis, face masks have evolved into everyday essentials—driven not only by pandemic preparedness but by rising air pollution, cultural shifts, and workplace safety regulations. As innovation and demand grow worldwide, the protective face mask market is poised for long-term expansion well beyond COVID-19.
Sharps Safety Starts with Us: Why Infection Preventionists Must Lead the Charge
August 3rd 2025Sharps injuries remain a silent but serious threat in health care that infection preventionists are uniquely equipped to confront. With underreporting widespread and safety devices underused, it’s time for IPs to step into a leadership role, using their expertise in systems thinking, education, and policy to build a culture where staff protection is as prioritized as patient care.
The Green Revolution in SPD: From Hidden Cost to Frontline Change
August 3rd 2025As climate change accelerates, health care’s environmental impact faces increased scrutiny, with sterile processing departments (SPDs) emerging as key change agents. Often behind the scenes, SPD professionals can lead sustainability by turning routine practices into ecofriendly protocols that protect both patient and planetary health.
